Infectious Disease Compendium

Cystic fibrosis


Epidemiologic Risks


Can get pneumonia from a variety of organisms, the odd ones include: P. aeruginosa, Burkholderia cepacia, M. avium intracellulare, M. abscessus Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, Burkholderia gladioli are some of the rarer organisms that are associated with CF.

Corynebacterium pseudodiphtheriticum as well (PubMed).

Empiric Therapy

Depends in part on prior cultures, therapies, and current gram stains; it usually involves cefepime OR ceftazadime OR carbapenem ie anti-pseudomonal antibiotics. Aerosolized tobramycin may be of benefit to preserve lung function and prevent infections in stable and mildly ill patients; perhaps inhaled aztreonam is better (Ref). In Cystic fibrosis patients, resistance to carbapenems can occur even if the patient has not been treated with these agents (PubMed).

Prior exposure to itraconazole leads to azole resistance in Aspergillus (PubMed).

Macrolides have been used in cystic fibrosis and sepsis where, despite in vitro resistance, the antibiotics improved outcomes. Pseudomonas may be resistant to macrolides in a test tube but when tested in cell culture have efficacy (PubMed).


If a young person, like in the mid-twenties presents with Pseudomonas pneumonia out the blue, think cystic fibrosis.